Effect of a low dose of gonadotropin releasing hormone antagonist on in vitro fertilization outcomes

Purpose This study aims to determine whether a low dose of the gonadotropin releasing hormone antagonist, cetrorelix, prevents a premature luteinizing hormone (LH) surge and affects in vitro fertilization (IVF) outcomes compared to the standard dose of 0.25 mg/day. Methods In this study, 45 IVF/intr...

Full description

Saved in:
Bibliographic Details
Published in:Archives of gynecology and obstetrics 2013-09, Vol.288 (3), p.691-695
Main Authors: Kerimoğlu, Özlem Seçilmiş, Ercan, Cihangir Mutlu, Keskin, Uğur, Korkmaz, Cem, Duru, Namık Kemal, Ergün, Ali
Format: Article
Language:English
Subjects:
Adult
Endocrinology
Female
Fertilization in Vitro
Gonadotropin-Releasing Hormone - administration & dosage
Gonadotropin-Releasing Hormone - analogs & derivatives
Gonadotropin-Releasing Hormone - antagonists & inhibitors
Gynecology
Human Genetics
Humans
In vitro fertilization
Luteinizing Hormone - secretion
Male
Medicine
Medicine & Public Health
Obstetrics/Perinatology/Midwifery
Ovulation Induction
Pregnancy
Pregnancy Rate
Reproductive Medicine
Retrospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose This study aims to determine whether a low dose of the gonadotropin releasing hormone antagonist, cetrorelix, prevents a premature luteinizing hormone (LH) surge and affects in vitro fertilization (IVF) outcomes compared to the standard dose of 0.25 mg/day. Methods In this study, 45 IVF/intracytoplasmic sperm injection patients were stimulated with recombinant follicle stimulation hormone from day 2 of the cycle. Cetrorelix was injected daily from day 6 of gonadotropin administration. Twenty-two patients received cetrorelix at a dose of 0.25 mg/day, whereas 23 participants received half dose. Results The mean consumption of gonadotropins was significantly higher in patients receiving 0.25 mg/day of cetrorelix (2,213 vs. 1,350 U; p  = 0.046). The clinical pregnancy rates were similar in both groups (31.8 vs. 47.8 %; p  = 0.273). Premature LH surge was detected in 9.1 % of the patients receiving cetrorelix 0.25 mg/day and in 13 % of the patients receiving cetrorelix 0.125 mg/day ( p  > 0.05). The difference between two groups was not statistically significant ( p  > 0.05). Conclusıons Our results suggest that there is no difference between a cetrorelix dose of 0.125 or 0.25 mg/day in preventing premature LH rise during ovarian stimulation for IVF.
ISSN:0932-0067
1432-0711
DOI:10.1007/s00404-013-2806-z